The Buck Buck Foundation is a non-profit 501 (c) (3) organization dedicated to the loving memory of Bryan Keith Robison, aka, Buck Buck, who bravely endured severe disabilities for 23 years due to CMV (Cytomegalovirus); a leading cause of childhood disability. The Buck Buck Foundation’s mission is to provide CMV medically fragile children and their families with financial support, education and hope. Our goal is to raise national awareness of CMV with the aim to prevent birth defects. Our objective is to collaborate with other existing organizations, and the medical community, for the wide adoption of CMV testing for women in their child-bearing years, and toward the development of finding a vaccine for CMV prevention. Our goal is to develop and provide Buck Buck homes to care for medically fragile children when care at home is no longer an option.
Board of Directors
Founder • President/FounderDar Hoogstad formed the Buck Buck Foundation in the loving memory of her eldest child, Bryan Keith Robison, aka, Buck Buck. Dar is an entrepreneur at heart, and holds many years of experience in the health and wellness, and architect and design industries. She has devoted countless hours to The Salvation Army and other prominent causes. Dar has two grown children, six grandchildren and resides with the love of her life in the Portland, Oregon Metropolitan area.
Julie St. Peter, RN
Healthcare AdviserJulie St. Peter is a registered nurse with 31 years of experience. She is involved in the health and nutrition industry, currently employed with Oregon Health and Science University and Portland Rheumatology. Julie is the mother of 2 sons, and brings a strong background of committee experience holding many board positions.
Mark Schleiss , Ph.D.
DirectorNot only is Dr. Mark Schleiss a Board of Director with the Buck Buck Foundation, but he also lends his expertise to the American Legion Endowed Professor of Pediatrics, and the Division of Pediatric Infectious Diseases at the University of Minnesota. His laboratory is broadly interested in the study of congenital Cytomegalovirus (CMV) transmission, including vaccines, antiviral drugs, newborn screening, and viral pathogenesis. Dr. Schleiss has developed an animal model of congenital CMV transmission, ideal for the study of CMV vaccines designed to protect the fetus. Using this guinea-pig model, protection against CMV transmission and disease can be engendered by vaccines targeting viral envelope glycoproteins, as well as, live attenuated vaccines. The recent encouraging results of a phase II study of a purified CMV glycoprotein in a population of young women at high risk for primary CMV infection has validated the value of the guinea-pig model, since preclinical studies of a similar vaccine in this model demonstrated protection against CMV transmission to the guinea-pig fetus. Dr. Schleiss is continuing to study a variety of vaccine strategies in this model, toward the goal of defining optimal ways of protecting newborns against the potentially devastating consequences of congenital CMV infection.